AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Insider Transactions Reported | Stoke Therapeutics(STOK)saw insider trading activity on 10/10/2025
ByAinvest
Friday, Oct 10, 2025 6:00 pm ET1min read
Stoke Therapeutics(STOK) saw insider trading activity on 10/10/2025, there were 2 insider trades during the day.
【History Insider Transaction】
| Declare date | Position | Name | Buy/Sell | Quantity | Price per share/USD | Total Amount/USD |
|---|---|---|---|---|---|---|
| 10/10/2025 | -- | Kaye Edward M. MD | Sell | 25000 | 30.00 | 750.0k |
| 10/10/2025 | -- | Kaye Edward M. MD | Buy | 25000 | 0.60 | 15.0k |
| 10/7/2025 | -- | Kaye Edward M. MD | Sell | 42461 | 25.09 | 1065.21k |
| 10/7/2025 | GENERAL COUNSEL & CORP SEC | Allan Jonathan | Sell | 10000 | 25.07 | 250.65k |
| 10/7/2025 | GENERAL COUNSEL & CORP SEC | Allan Jonathan | Buy | 10000 | 9.15 | 91.5k |
| 10/3/2025 | CHIEF MEDICAL OFFICER | Ticho Barry | Sell | 5343 | 23.64 | 126.32k |
| 9/3/2025 | CHIEF MEDICAL OFFICER | Ticho Barry | Sell | 5501 | 19.87 | 109.33k |
| 9/3/2025 | GENERAL COUNSEL & CORP SEC | Allan Jonathan | Buy | 10000 | 7.07 | 70.7k |
| 9/3/2025 | GENERAL COUNSEL & CORP SEC | Allan Jonathan | Sell | 14922 | 20.14 | 300.49k |
| 9/3/2025 | -- | Kaye Edward M. MD | Sell | 1029 | 20.00 | 20.58k |
[Company Profile]
Stoke Therapeutics, Inc. was founded in June 2014 and was incorporated under the laws of the State of Delaware. The Company is an early-stage biopharmaceutical company pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression. The company is developing novel antisense oligonucleotide, or ASO, medicines that target ribonucleic acid, or RNA, and modulate precursor-messenger RNA, or pre-mRNA, splicing to upregulate protein expression where needed and with appropriate specificity to near normal levels. The company utilize proprietary technology platform, Targeted Augmentation of Nuclear Gene Output, or TANGO, to design ASOs to upregulate the expression of protein by individual genes in a patient. The company approach is designed to deliver in a highly precise, durable and controlled manner disease-modifying therapies to a wide range of relevant tissues, including the central nervous system, or CNS, eye, kidney and liver.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet